Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: Implications for cancer risk stratification and biomarker sampling

Human Pathology

Volumn 46, Issue 5, 2015, Pages 698-706

  Shah, Rajal B ^a   Bentley, James ^a   Jeffery, Zach ^a   Demarzo, Angelo M ^b  

^a MIRACA LIFE SCIENCES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; ERG; Heterogeneity; Prostate cancer; Prostate needle biopsy; PTEN

Indexed keywords

BIOLOGICAL MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR ERG; ERG PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER RISK; CANCER SIZE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE SEVERITY; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; NEEDLE BIOPSY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CORE BIOPSY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; LARGE CORE NEEDLE BIOPSY; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RISK;

BIOPSY, LARGE-CORE NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RISK; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84930985267     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.01.008     Document Type: Article

References (42)

1. R.B. Shah, R. Mehra, A.M. Chinnaiyan, and et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program Cancer Res 64 2004 9209 9216
2. H. Huland, M. Graefen, A. Haese, and et al. Prediction of tumor heterogeneity in localized prostate cancer Urol Clin North Am 29 2002 213 222
3. R. Mehra, B. Han, S.A. Tomlins, and et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases Cancer Res 67 2007 7991 7995
4. V. Nwosu, J. Carpten, J.M. Trent, and R. Sheridan Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease Hum Mol Genet 10 2001 2313 2318
5. G.J. Miller, and J.M. Cygan Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration J Urol 152 1994 1709 1713
6. A.M. Wise, T.A. Stamey, J.E. McNeal, and J.L. Clayton Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens Urology 60 2002 264 269
7. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, L.L. Egevad, and ISUP Grading Committee The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242
8. R. Arora, M.O. Koch, J.N. Eble, and et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate Cancer 100 2004 2362 2366
9. B. Han, R. Mehra, R.J. Lonigro, and et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression Mod Pathol 22 2009 1083 1093
10. R. Mehra, S.A. Tomlins, R. Shen, and et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer Mod Pathol 20 2007 538 544
11. R. Mehra, S.A. Tomlins, J. Yu, and et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer Cancer Res 68 2008 3584 3590
12. R.B. Shah, and A.M. Chinnaiyan The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications Adv Anat Pathol 16 2009 145 153
13. S.A. Tomlins, D.R. Rhodes, S. Perner, and et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
14. M. Yoshimoto, J.C. Cutz, P.A. Nuin, and et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias Cancer Genet Cytogenet 169 2006 128 137
15. J.M. Mosquera, R. Mehra, M.M. Regan, and et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States Clin Cancer Res 15 2009 4706 4711
16. J.M. Mosquera, S. Perner, E.M. Genega, and et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications Clin Cancer Res 14 2008 3380 3385
17. S. Perner, J.M. Mosquera, F. Demichelis, and et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion Am J Surg Pathol 31 2007 882 888
18. R.B. Shah Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management Adv Anat Pathol 20 2013 117 124
19. R.B. Shah, Y. Tadros, B. Brummell, and M. Zhou The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and alpha-methylacyl-CoA-racemase markers Hum Pathol 44 2013 786 794
20. S.A. Tomlins, N. Palanisamy, J. Siddiqui, A.M. Chinnaiyan, and L.P. Kunju Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies Arch Pathol Lab Med 136 2012 935 946
21. A. Pettersson, R.E. Graff, S.R. Bauer, and et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis Cancer Epidemiol Biomarkers Prev 21 2012 1497 1509
22. B. Furusato, S.H. Tan, D. Young, and et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification Prostate Cancer Prostatic Dis 13 2010 228 237
23. P. Rosen, I.A. Sesterhenn, S.A. Brassell, and et al. Clinical potential of the ERG oncoprotein in prostate cancer Nat Rev Urol 9 2012 131 137
24. L.M. Johnson, B. Turkbey, W.D. Figg, and P.L. Choyke Multiparametric MRI in prostate cancer management Nat Rev Clin Oncol 11 2014 346 353
25. J.C. Brenner, B. Ateeq, Y. Li, and et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Cancer Cell 19 2011 664 678
26. T.L. Lotan, B. Gurel, S. Sutcliffe, and et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients Clin Cancer Res 17 2011 6563 6573
27. J. Bertram, J.W. Peacock, L. Fazli, and et al. Loss of PTEN is associated with progression to androgen independence Prostate 66 2006 895 902
28. A. Chaux, S.B. Peskoe, N. Gonzalez-Roibon, and et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer Mod Pathol 25 2012 1543 1549
29. A. Krohn, T. Diedler, L. Burkhardt, and et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer Am J Pathol 181 2012 401 412
30. M.E. McMenamin, P. Soung, S. Perera, and et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage Cancer Res 59 1999 4291 4296
31. M. Yoshimoto, I.W. Cunha, R.A. Coudry, and et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome Br J Cancer 97 2007 678 685
32. A.H. Reid, G. Attard, L. Ambroisine, and et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer Br J Cancer 102 2010 678 684
33. P. Mithal, E. Allott, L. Gerber, and et al. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer Int J Urol 21 2014 1209 1214
34. T.L. Lotan, F.L. Carvalho, S.B. Peskoe, and et al. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy Mod Pathol 28 2015 128 137
35. B. Gumuskaya, B. Gurel, H. Fedor, and et al. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion Prostate Cancer Prostatic Dis 16 2013 209 215
36. A. Krohn, F. Freudenthaler, S. Harasimowicz, and et al. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer Mod Pathol 27 2014 1612 1620
37. M. Yoshimoto, K. Ding, J.M. Sweet, and et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade Mod Pathol 26 2013 435 447
38. A. Chaux, R. Albadine, A. Toubaji, and et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas Am J Surg Pathol 35 2011 1014 1020
39. K. Park, S.A. Tomlins, K.M. Mudaliar, and et al. Antibody-based detection of ERG rearrangement-positive prostate cancer Neoplasia 12 2010 590 598
40. G.J. van Leenders, J.L. Boormans, C.J. Vissers, and et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice Mod Pathol 24 2011 1128 1138
41. L.H. Teng, C. Wang, L.R. Begin, and et al. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease Urology 82 2013 394 399
42. A.M. Udager, Y. Shi, S.A. Tomlins, and et al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer Prostate 74 2014 1199 1208